On May 16, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, reported that the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) has published an abstract on the Company’s clinical study evaluating its lead candidate, DPX-Survivac, in recurrent advanced ovarian cancer (Press release, IMV, MAY 16, 2019, View Source [SID1234536445]). The abstract was released online on the ASCO (Free ASCO Whitepaper) website yesterday in advance of ASCO (Free ASCO Whitepaper)’s annual meeting in Chicago, Illinois, taking place May 31 – June 4, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The final conference poster presentation will include additional data collected between the abstract submission cutoff date of February 12, 2019, and the presentation itself.

Conference Call and Webcast Information

IMV will host a webcast and conference call to provide an overview of its ASCO (Free ASCO Whitepaper) presentation on Sunday, June 2, 2019 at 9:00 a.m. ET. The conference line is (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (International), and the conference ID# is 8579285. A live audio webcast and presentation will be available via this link and through the ‘Events and Presentations’ page of IMV’s website.

IMV ASCO (Free ASCO Whitepaper) 2019 Presentation Detail

Poster Title: "DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression."
Abstract Number: 5576
Session Title: Gynecologic Cancer
Date and Time: June 1, 2019, 1:15 – 4:15 p.m. CT

About DPX-Survivac

DPX-Survivac is the lead candidate in IMV’s new class of immunotherapies that programs targeted T cells in vivo. It has demonstrated the potential for industry-leading targeted, persistent, and durable T cell activation. IMV believes this mechanism of action (MOA) is key to generating durable solid tumor regressions. DPX-Survivac consists of survivin-based peptides formulated in IMV’s proprietary DPX drug delivery platform. DPX-Survivac is designed to work by eliciting a cytotoxic T cell immune response against cancer cells presenting survivin peptides on their surface.

Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to anti-cancer therapies. IMV has identified over 15 cancer indications in which the over-expression of survivin can be targeted by DPX-Survivac.

DPX-Survivac has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication. It is currently being evaluated in multiple Phase 1b/2 clinical trials.

On May 16, 2019 Oncorus, Inc., an oncolytic virus therapeutics company focused on driving innovation to transform outcomes for cancer patients, reported that its President and Chief Executive Officer, Ted Ashburn, M.D., Ph.D., will provide a company overview and pipeline update at the following upcoming healthcare investor conferences in New York City (Press release, Oncorus, MAY 16, 2019, View Source [SID1234536444]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Global Healthcare Conference on Tuesday, May 21, 2019 at 1:30 p.m. ET
Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 9:30 a.m. ET

On May 16, 2019 ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, reported that ALX148 clinical results have been selected for presentation in the Poster Discussion Session at the 2019 ASCO (Free ASCO Whitepaper) Annual Meeting, May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois (Press release, ALX Oncology, MAY 16, 2019, View Source [SID1234536443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALX148 Presentation Information

Title: A phase 1 study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy (Abstract #2514).

Poster Discussion Session: Developmental Immunotherapy and Tumor Immunobiology, Advances in Immune Checkpoint Inhibition

Date: Saturday, June 1

Time: 1:15 p.m. – 1:27 p.m.

Location: Hall D1

Poster Display Session: Developmental Immunotherapy and Tumor Immunobiology

Date: Saturday, June 1

Time: 8:00 a.m. – 11:00 a.m.

Location: Hall A

On May 16, 2019 Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas (Press release, Zymeworks, MAY 16, 2019, View Source [SID1234536442]). Under the expanded agreement, GSK will now have access to Zymeworks’ unique heavy-light chain pairing technology, part of its proprietary Azymetric platform. Zymeworks’ Azymetric platform enables the development of bispecific and multifunctional therapeutics while maintaining the characteristics of naturally-occurring human antibodies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to see GSK broaden their technology license and believe that it reflects their increased commitment to develop differentiated bispecific therapeutics," said Ali Tehrani, Ph.D., President and CEO of Zymeworks. "As part of this expansion, GSK expects to use our Azymetric technology to develop bispecifics for the treatment of infectious diseases, which highlights the utility of our platform beyond traditional indications like oncology and inflammatory disease."

Under the updated terms of the expanded agreement, GSK will have the option to develop and commercialize bispecific drugs across different disease areas and Zymeworks will be eligible to receive increased preclinical, development and commercial milestone payments. If all six programs are developed and commercialized, the new potential value of the collaboration would be up to US$1.1 billion. Additionally, Zymeworks is eligible to receive increased tiered royalties on worldwide sales.

About the Azymetric Platform

The Azymetric platform enables the transformation of monospecific antibodies into bispecific antibodies, giving the antibodies the ability to simultaneously bind two different targets. Azymetric bispecific technology enables the development of multifunctional biotherapeutics that can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering degradation, and increase tumor-specific targeting. These features are intended to enhance efficacy while reducing toxicities and the potential for drug resistance. Azymetric bispecifics have been engineered to retain the desirable drug-like qualities of naturally occurring antibodies, including low immunogenicity, long half-life, and high stability. In addition, they are compatible with standard manufacturing processes with high yields and purity, potentially significantly reducing drug development costs and timelines.

On May 16, 2019 Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported the presentation of updated clinical data for its potent and highly selective investigational medicines avapritinib and BLU-667 (Press release, Blueprint Medicines, MAY 16, 2019, View Source [SID1234536441]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and 24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), Blueprint Medicines plans to present:

Data from the expansion portion of the registration-enabling ARROW trial of BLU-667 in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancers
Data from the registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant and fourth-line gastrointestinal stromal tumors (GIST), which will be used for planned marketing applications in the United States and Europe
Data from the registration-enabling EXPLORER trial of avapritinib in patients with advanced systemic mastocytosis (SM)
"Our upcoming presentations highlight data supporting our plans for multiple marketing applications in the United States and Europe over the next 18 months and demonstrate continued progress on our ‘2020 Blueprint’ strategy," said Andy Boral, M.D., Ph.D., Chief Medical Officer of Blueprint Medicines. "The datasets reflect the rapid development of avapritinib and BLU-667, including in four indications that have received Breakthrough Therapy Designation from the FDA. These presentations for avapritinib and BLU-667 highlight the breadth and speed of development of our portfolio, as well as our commitment to rapidly deliver new precision therapies to cancer patients with limited or no effective treatment options."

The accepted abstracts are listed below and are now available online on the ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) conference websites, respectively: View Source and View Source

2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting
May 31-June 4, 2019; Chicago, Illinois

Oral Presentation

Presentation Title: Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date & Time: Monday, June 3, 2019 from 8:00 a.m. – 11:00 a.m. CT (9:00 a.m. – 12:00 p.m. ET)
Abstract Number: 9008

Poster Discussion Presentations

Presentation Title: Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers
Session Title: Head and Neck Cancer
Poster Session Date & Time: Saturday, June 1, 2019 from 1:15 p.m. – 4:15 p.m. CT (2:15 p.m. – 5:15 p.m. ET)
Poster Discussion Session Date & Time: Saturday, June 1, 2019 from 4:30 – 6:00 p.m. CT (5:30 p.m. – 7:00 p.m. ET)
Abstract Number: 6018

Presentation Title: Clinical activity of avapritinib in ≥ fourth line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST)
Session Title: Sarcoma
Poster Session Date & Time: Saturday, June 1, 2019 from 8:00 a.m. – 11:00 a.m. CT (9:00 a.m. – 12:00 p.m. ET)
Poster Discussion Session Date & Time: Saturday, June 1, 2019 from 3:00 p.m. – 4:30 p.m. CT (4:00 p.m. – 5:30 p.m. ET)
Abstract Number: 11022

24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper)
June 13-16, 2019; Amsterdam, The Netherlands

Oral Presentation

Presentation Title: Avapritinib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (AdvSM)
Session Title: New Agents in MPN
Presentation Date & Time: Saturday, June 15, 2019 from 12:00 p.m. – 12:15 p.m. CEST (6:00 a.m. – 6:15 a.m. ET)
Abstract Number: S830

Investor Event and Webcast Information

Blueprint Medicines will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to provide a portfolio update, including a review of updated clinical data from the ongoing ARROW trial of BLU-667 in patients with RET-altered cancers and the ongoing registration-enabling NAVIGATOR trial in patients with PDGFRA Exon 18 mutant and fourth-line GIST. The event will be webcast live and can be accessed under the "Investors & Media—Events & Presentations" section of Blueprint Medicines’ website at www.BlueprintMedicines.com. A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.